ClinicalTrials.gg
CompletedNCT03192137ISV-305Updated Nov 19, 2021Results posted

Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

A Phase 3 interventional study of ISV-305 and Vehicle in Inflammation and Pain Associated With Cataract Surgery, sponsored by Sun Pharmaceutical Industries Limited. Completed at 1 site in United States. Open to participants aged 17 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
17 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing dexamethasone in Inflammation — 1 open to participants now, 2 under way, 2 of them phase 3. Dexamethasone · Inflammation.

Enrollment
5th of 14
260 · median 132
Started
2018
with 1 other
Phase 3
4 of 14
none open now
Registered
5th of 14
by date
Lead sponsor
2 of 14
Sun Pharmaceutical Industries Limited

Among the 14 studies testing dexamethasone in Inflammation, this one is the 5th largest by enrollment, is one of 2 that started in 2018, is one of 4 in phase 3, and was the 5th registered.

Inflammation

3,541 studies on the registry are indexed under Inflammation; 645 are open to participants now.

Browse Inflammation studies →

Open to participants now

1 of the 14 studies testing dexamethasone in Inflammation is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 461 Inflammation studies recruiting now, 174 (38%) set no upper age limit and 206 (45%) stop at 75 or younger; 56 take children under 18; 165 take healthy volunteers.

This study: 17 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing dexamethasone in Inflammation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of ISV-305 (dexamethasone in DuraSite® 2) compared with Vehicle in the treatment of inflammation and pain associated with cataract surgery.

Read the detailed description

The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of topical administration of ISV-305 (0.1% dexamethasone in DuraSite® 2) compared with Vehicle when dosed twice daily for 1 day prior to surgery, the day of surgery and 14 days post cataract surgery.

03

Conditions studied

  • Inflammation and Pain Associated With Cataract Surgery

Browse trials for

04

Who can participate

Ages eligible
17 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are at least 17 years of age
  • Are scheduled for uncomplicated unilateral cataract surgery
  • Signature of the subject or parent(s) or legally authorized representative on the Form, and when appropriate the minor's assent in accordance with local regulations
  • Are willing and able to follow all instructions and attend all study visits
  • Are willing to avoid disallowed medication for the duration of the study
  • If female is of , agree to and submit a urine sample for pregnancy testing (prior to enrollment and at the end of the study) and use effective for the duration of the study
  • Male subjects whose female partners are not must agree to one of the following: 1) completely abstain from sexual intercourse, 2) use a barrier method (condoms) with spermicide during sexual intercourse for the duration of the study, 3) provide documentation for having had a vasectomy (with documented infertility)
  • Additional inclusion criteria also apply

Exclusion criteria

Exclusion Criteria:

  • Have known sensitivity or poor tolerance to any component of the study drugs
  • Have any sign of iritis or scleritis in the study eye
  • Have an acute ocular infection (bacterial, viral or fungal) or active ocular inflammation in the study eye
  • Have any active or chronic/recurrent ocular or systemic disease that is uncontrolled and likely to affect wound healing (e.g., diabetes mellitus, systemic connective tissue disease, severe atopic disease)
  • Have known blood dyscrasia or bone marrow suppression
  • Have any active corneal pathology in the study eye
  • Have had radial keratotomy, corneal transplant, or LASIK in the study eye within the last 2 years
  • Be currently pregnant, nursing, or planning a pregnancy; or have a positive urine pregnancy test
  • Have prior (within 30 days of beginning study treatment) or anticipated concurrent use of an drug or device
  • Have a condition or a situation which, in the investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation
  • Use of any medication the investigator feels may interfere with the study parameters
  • Additional exclusion criteria also apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    ISV-305

    0.1% dexamethasone in DuraSite® 2

    Drug: ISV-305

  • Placebo comparator
    Vehicle

    DuraSite® 2 Vehicle

    Other: Vehicle

Interventions

  • Dexamethasone in DuraSite® 2 twice daily for 16 days

  • OtherVehicle

    Vehicle twice daily for 16 days

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Anterior Chamber Cell (ACC) Grade 0 in Study Eye at Day 15 (Last Observation Carried Forward) in the Modified Intent to Treat (mITT) Population

    Biomicroscopic measurement of anterior chamber cells was conducted in the surgery eye (study eye) by the same examiner from visit to visit whenever possible. A slit-lamp biomicroscope was used at x16 magnification with a 1 x 1 mm oblique high-intensity beam. Two cell counts were summed and divided by 2 to determine an average final anterior chamber cell count. This final cell count was converted to a grade: Grades 0, 1, 2, 3, 4 were assigned for cell counts of 0, 1 to 10, 11 to 20, 21 to 50, and \> 50, respectively. If the averaged count fell between two grades, the higher grade was selected (e.g., if the two counts were 10 and 11, the average of 10.5 fell into Grade 2). Missing anterior chamber cell grade at Day 15 was imputed by last non-missing scheduled post-baseline anterior chamber cell grade assessed prior to Day 15 (last observation carried forward).

    Time frame: Day 15

Secondary outcomes

  1. Proportion of Participants Who Achieved a Pain Score of 0 on the Visual Analog Scale (VAS) for Each Post-surgical Assessment

    Eye pain/discomfort in the study eye was evaluated at every visit except Visit 2 (Surgery; Day 0) using a VAS, scoring from 0 to 100 using a mark on a 100 mm line (0 = absent; 100 = maximum). Participants were asked to rate the feeling of the symptom in the study eye from absent to extreme by moving a slide on the side of the scale to align with images of descriptive faces.

    Time frame: Day 1 to Day 29

07

Results

Posted Jun 29, 2020

Participant flow

Participant flow — Overall Study
MilestoneISV-305Vehicle
Started17387
Completed12329
Not completed5058
Withdrew: Adverse event1011
Withdrew: Physician decision10
Withdrew: Lack of efficacy2037
Withdrew: Withdrawal by subject33
Withdrew: Protocol violation43
Withdrew: Surgery cancelled41
Withdrew: Other - various administrative reasons83

Outcome measures

PrimaryProportion of Participants With Anterior Chamber Cell (ACC) Grade 0 in Study Eye at Day 15 (Last Observation Carried Forward) in the Modified Intent to Treat (mITT) Population

Biomicroscopic measurement of anterior chamber cells was conducted in the surgery eye (study eye) by the same examiner from visit to visit whenever possible. A slit-lamp biomicroscope was used at x16 magnification with a 1 x 1 mm oblique high-intensity beam. Two cell counts were summed and divided by 2 to determine an average final anterior chamber cell count. This final cell count was converted to a grade: Grades 0, 1, 2, 3, 4 were assigned for cell counts of 0, 1 to 10, 11 to 20, 21 to 50, and \> 50, respectively. If the averaged count fell between two grades, the higher grade was selected (e.g., if the two counts were 10 and 11, the average of 10.5 fell into Grade 2). Missing anterior chamber cell grade at Day 15 was imputed by last non-missing scheduled post-baseline anterior chamber cell grade assessed prior to Day 15 (last observation carried forward).

Time frame:
Day 15
Reported as:
Number · participants
Proportion of Participants With Anterior Chamber Cell (ACC) Grade 0 in Study Eye at Day 15 (Last Observation Carried Forward) in the Modified Intent to Treat (mITT) Population
participantsISV-305Vehicle
0 (did not receive rescue therapy)6916
0 (received rescue therapy)00
16430
2510
3612
404
Statistical analysis
  • ISV-305 vs Vehicle · Chi-squared, Corrected · p = 0.0005 (P-values were from a Chi-Square test (with continuity correction) of differences between treatments in the proportion of participants with anterior chamber cells Grade 0 who did not receive rescue medication versus all other grades combined.)A Fisher's exact test was used if 1 or more of the cells had an expected frequency of ≤ 5.
SecondaryProportion of Participants Who Achieved a Pain Score of 0 on the Visual Analog Scale (VAS) for Each Post-surgical Assessment

Eye pain/discomfort in the study eye was evaluated at every visit except Visit 2 (Surgery; Day 0) using a VAS, scoring from 0 to 100 using a mark on a 100 mm line (0 = absent; 100 = maximum). Participants were asked to rate the feeling of the symptom in the study eye from absent to extreme by moving a slide on the side of the scale to align with images of descriptive faces.

Time frame:
Day 1 to Day 29
Reported as:
Number · Participants
Proportion of Participants Who Achieved a Pain Score of 0 on the Visual Analog Scale (VAS) for Each Post-surgical Assessment
ParticipantsISV-305Vehicle
Pain Score of 0 on Day 110329
Pain Score of 0 on Day 813344
Pain Score of 0 on Day 1513749
Pain Score of 0 on Day 1812950
Pain Score of 0 on Day 2913551
Statistical analysis
  • ISV-305 vs Vehicle · Chi-squared, Corrected · p = <0.0001 (P-values were from a Chi-Square test (with continuity correction).) · Odds ratio (or): 3.217 · 95% CI 1.823 to 5.675A Fisher's exact test was used if 1 or more of the cells had an expected frequency of ≤ 5.
  • ISV-305 vs Vehicle · Chi-squared, Corrected · p = <0.0001 (P-values were from a Chi-Square test (with continuity correction).) · Odds ratio (or): 4.337 · 95% CI 2.305 to 8.161A Fisher's exact test was used if 1 or more of the cells had an expected frequency of ≤ 5.
  • ISV-305 vs Vehicle · Chi-squared, Corrected · p = <0.0001 (P-values were from a Chi-Square test (with continuity correction).) · Odds ratio (or): 4.120 · 95% CI 2.113 to 8.033A Fisher's exact test was used if 1 or more of the cells had an expected frequency of ≤ 5.
  • ISV-305 vs Vehicle · Chi-squared, Corrected · p = 0.0043 (P-values were from a Chi-Square test (with continuity correction).) · Odds ratio (or): 2.580 · 95% CI 1.380 to 4.822A Fisher's exact test was used if 1 or more of the cells had an expected frequency of ≤ 5.
  • ISV-305 vs Vehicle · Chi-squared, Corrected · p = 0.0005 (P-values were from a Chi-Square test (with continuity correction).) · Odds ratio (or): 3.277 · 95% CI 1.695 to 6.335A Fisher's exact test was used if 1 or more of the cells had an expected frequency of ≤ 5.

Adverse events

Collected over Adverse events (AEs) were reported from the date of signing the consent form to the date of completion of the participant's final visit (Day 29). Ongoing AEs were followed beyond the final study visit at the discretion of the investigator.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ISV-3050/158 (0%)3/158 (1.9%)31/158 (19.6%)
Vehicle0/80 (0%)0/80 (0%)21/80 (26.3%)
Most frequent serious events
Most frequent serious events
EventISV-305Vehicle
Chest painGeneral disorders1/1580/80
Atrial flutterCardiac disorders1/1580/80
Blood magnesium decreasedInvestigations1/1580/80
VomitingGastrointestinal disorders1/1580/80
Pulmonary thrombosisRespiratory, thoracic and mediastinal disorders1/1580/80
Most frequent other events
Most frequent other events
EventISV-305Vehicle
Intraocular pressure increasedInvestigations10/1582/80
IritisEye disorders6/1585/80
Eye painEye disorders3/1584/80
Eye inflammationEye disorders1/1584/80
Visual acuity reducedEye disorders7/1582/80
Cystoid macular oedemaEye disorders2/1583/80
Foreign body sensation in eyesEye disorders2/1583/80
Visual impairmentEye disorders4/1581/80
HeadacheNervous system disorders1/1582/80

Baseline characteristics

Demographics were summarized for the Safety Population which included all randomized participants who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(Years)ISV-305VehicleTotal
Mean68.0 ± 7.1568.5 ± 9.3768.2 ± 7.95
Sex: Female, Male
Sex: Female, Male(Participants)ISV-305VehicleTotal
Female9443137
Male6437101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ISV-305VehicleTotal
American Indian or Alaska Native101
Asian426
Native Hawaiian or Other Pacific Islander000
Black or African American10515
White14172213
Mixed011
Other202
08

Study locations

1 site
  • Clinical Research Center
    Memphis, Tennessee 38120, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Apr 2019, 14 months.

Results were first posted in Jun 2020, 1 year 2 months after primary completion.

Of 21 industry-sponsored phase 3 interventional studies under Inflammation, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 28. This study's 14 months is below that.

Counting every sponsor, half of 68 studies reached it within 27 months; a quarter within 17 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2017
First posted
Jun 19, 2017
StartActual
Jan 30, 2018
Primary completionActual
Apr 17, 2019
CompletionActual
Apr 17, 2019
Results first posted
Jun 29, 2020
Last update
Nov 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03192137
Responsible party
Sponsor
First posted
Jun 19, 2017
Start date
Jan 30, 2018
Primary completion
Apr 17, 2019
Completion
Apr 17, 2019
Results posted
Jun 29, 2020
Last update
Nov 19, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion